JP2008526771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526771A5 JP2008526771A5 JP2007549683A JP2007549683A JP2008526771A5 JP 2008526771 A5 JP2008526771 A5 JP 2008526771A5 JP 2007549683 A JP2007549683 A JP 2007549683A JP 2007549683 A JP2007549683 A JP 2007549683A JP 2008526771 A5 JP2008526771 A5 JP 2008526771A5
- Authority
- JP
- Japan
- Prior art keywords
- zinc
- pharmaceutical composition
- composition according
- polymer
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229920000642 polymer Polymers 0.000 claims 10
- 150000003751 zinc Chemical class 0.000 claims 10
- 229920000083 poly(allylamine) Polymers 0.000 claims 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims 8
- 239000011787 zinc oxide Substances 0.000 claims 6
- 235000014692 zinc oxide Nutrition 0.000 claims 6
- 239000003431 cross linking reagent Substances 0.000 claims 4
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 claims 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 4
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 claims 4
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims 4
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical group [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims 3
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical group NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 claims 3
- 229960003693 sevelamer Drugs 0.000 claims 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims 3
- 239000004246 zinc acetate Substances 0.000 claims 3
- 235000013904 zinc acetate Nutrition 0.000 claims 3
- 239000011667 zinc carbonate Substances 0.000 claims 3
- 235000004416 zinc carbonate Nutrition 0.000 claims 3
- 229910000010 zinc carbonate Inorganic materials 0.000 claims 3
- 239000011746 zinc citrate Substances 0.000 claims 3
- 235000006076 zinc citrate Nutrition 0.000 claims 3
- 229940068475 zinc citrate Drugs 0.000 claims 3
- VRGNUPCISFMPEM-ZVGUSBNCSA-L zinc;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Zn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VRGNUPCISFMPEM-ZVGUSBNCSA-L 0.000 claims 3
- JMZRZEXRYJUHEB-UHFFFAOYSA-N 2-carbamothioylsulfanylethyl carbamodithioate;zinc Chemical compound [Zn].NC(=S)SCCSC(N)=S JMZRZEXRYJUHEB-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims 2
- 239000004110 Zinc silicate Substances 0.000 claims 2
- 239000005083 Zinc sulfide Substances 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 229940105847 calamine Drugs 0.000 claims 2
- MFGZXPGKKJMZIY-UHFFFAOYSA-N ethyl 5-amino-1-(4-sulfamoylphenyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC=C(S(N)(=O)=O)C=C1 MFGZXPGKKJMZIY-UHFFFAOYSA-N 0.000 claims 2
- 229910052864 hemimorphite Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- MJIBOYFUEIDNPI-HBNMXAOGSA-L zinc 5-[2,3-dihydroxy-5-[(2R,3R,4S,5R,6S)-4,5,6-tris[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]-2-[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxymethyl]oxan-3-yl]oxycarbonylphenoxy]carbonyl-3-hydroxybenzene-1,2-diolate Chemical compound [Zn++].Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c([O-])c([O-])c2)c1 MJIBOYFUEIDNPI-HBNMXAOGSA-L 0.000 claims 2
- 229940102001 zinc bromide Drugs 0.000 claims 2
- 239000011592 zinc chloride Substances 0.000 claims 2
- 235000005074 zinc chloride Nutrition 0.000 claims 2
- SRWMQSFFRFWREA-UHFFFAOYSA-M zinc formate Chemical compound [Zn+2].[O-]C=O SRWMQSFFRFWREA-UHFFFAOYSA-M 0.000 claims 2
- -1 zinc hexafluorosilicate Chemical compound 0.000 claims 2
- 239000011576 zinc lactate Substances 0.000 claims 2
- 235000000193 zinc lactate Nutrition 0.000 claims 2
- 229940050168 zinc lactate Drugs 0.000 claims 2
- XSMMCTCMFDWXIX-UHFFFAOYSA-N zinc silicate Chemical compound [Zn+2].[O-][Si]([O-])=O XSMMCTCMFDWXIX-UHFFFAOYSA-N 0.000 claims 2
- 235000019352 zinc silicate Nutrition 0.000 claims 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 2
- 229960001763 zinc sulfate Drugs 0.000 claims 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims 2
- 229910052984 zinc sulfide Inorganic materials 0.000 claims 2
- 229940006174 zinc valerate Drugs 0.000 claims 2
- LPEBYPDZMWMCLZ-CVBJKYQLSA-L zinc;(z)-octadec-9-enoate Chemical compound [Zn+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O LPEBYPDZMWMCLZ-CVBJKYQLSA-L 0.000 claims 2
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L zinc;4-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 ZNVKGUVDRSSWHV-UHFFFAOYSA-L 0.000 claims 2
- MFMKGXZULQONRI-UHFFFAOYSA-L zinc;diiodate Chemical compound [Zn+2].[O-]I(=O)=O.[O-]I(=O)=O MFMKGXZULQONRI-UHFFFAOYSA-L 0.000 claims 2
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims 2
- CHJMFFKHPHCQIJ-UHFFFAOYSA-L zinc;octanoate Chemical compound [Zn+2].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O CHJMFFKHPHCQIJ-UHFFFAOYSA-L 0.000 claims 2
- ZPEJZWGMHAKWNL-UHFFFAOYSA-L zinc;oxalate Chemical compound [Zn+2].[O-]C(=O)C([O-])=O ZPEJZWGMHAKWNL-UHFFFAOYSA-L 0.000 claims 2
- BUDAIZWUWHWZPQ-UHFFFAOYSA-L zinc;pentanoate Chemical compound [Zn+2].CCCCC([O-])=O.CCCCC([O-])=O BUDAIZWUWHWZPQ-UHFFFAOYSA-L 0.000 claims 2
- XDWXRAYGALQIFG-UHFFFAOYSA-L zinc;propanoate Chemical compound [Zn+2].CCC([O-])=O.CCC([O-])=O XDWXRAYGALQIFG-UHFFFAOYSA-L 0.000 claims 2
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 claims 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64064304P | 2004-12-30 | 2004-12-30 | |
| PCT/US2005/047582 WO2006072054A1 (en) | 2004-12-30 | 2005-12-29 | Zinc-containing treatments for hyperphosphatemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526771A JP2008526771A (ja) | 2008-07-24 |
| JP2008526771A5 true JP2008526771A5 (https=) | 2008-12-04 |
Family
ID=36143353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549683A Withdrawn JP2008526771A (ja) | 2004-12-30 | 2005-12-29 | 高リン酸血症のための亜鉛含有処置 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080014288A1 (https=) |
| EP (1) | EP1830832A1 (https=) |
| JP (1) | JP2008526771A (https=) |
| WO (1) | WO2006072054A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| EP1324348A1 (en) | 2001-12-28 | 2003-07-02 | STMicroelectronics S.r.l. | Autotesting method of a memory cells matrix, particularly of the non-volatile type |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| US20080160001A1 (en) * | 2005-03-28 | 2008-07-03 | Pficker Pharmaceuticals Ltd. | Antihypercholesterolemic Formulation with Less Side-Effects |
| EP3000460A1 (en) * | 2005-09-15 | 2016-03-30 | Genzyme Corporation | Sachet formulation for amine polymers |
| US11510894B2 (en) | 2006-01-27 | 2022-11-29 | John P. Geibel | Fast acting inhibitor of gastric acid secretion |
| US8512761B2 (en) | 2006-01-27 | 2013-08-20 | Yale University | Fast acting inhibitor of gastric acid secretion |
| US12527820B2 (en) | 2014-12-01 | 2026-01-20 | Vector Vitale Ip Llc | Pharmaceutical composition and method for suppressing degeneration |
| US10226484B2 (en) | 2014-12-01 | 2019-03-12 | Peter Y Novak | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| US10245284B2 (en) | 2015-08-19 | 2019-04-02 | Alpex Pharma S.A. | Granular composition for oral administration |
| US10183041B2 (en) | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
| TW201922249A (zh) * | 2017-09-29 | 2019-06-16 | 日商第一三共股份有限公司 | 二羧酸化合物與磷吸附劑之組合 |
| US11484610B2 (en) | 2019-11-22 | 2022-11-01 | Vector Vitale Ip Llc | Method of treating melanoma |
| US10933091B1 (en) | 2019-12-20 | 2021-03-02 | Vector Vitale Ip Llc | Composition and method for the treatment of type I diabetes |
| US10799530B1 (en) | 2019-12-20 | 2020-10-13 | Vector Vitale Ip Llc | Composition and method for the prevention and treatment of obesity |
| US11596650B2 (en) | 2019-12-20 | 2023-03-07 | Vector Vitale Ip Llc | Composition and method for the treatment of type 2 diabetes |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2456428A (en) * | 1944-10-11 | 1948-12-14 | Shell Dev | Polyallyl amine and related polymeric amines |
| US3104205A (en) * | 1959-12-17 | 1963-09-17 | Warner Lambert Pharmaceutical | Deodorant composition comprising the copper complex of the copolymer of allylamine and methacrylic acid |
| US3308020A (en) * | 1961-09-22 | 1967-03-07 | Merck & Co Inc | Compositions and method for binding bile acids in vivo including hypocholesteremics |
| US3332841A (en) * | 1961-10-04 | 1967-07-25 | Lilly Co Eli | Method of treating hyperacidity |
| US3624209A (en) * | 1966-12-28 | 1971-11-30 | Bristol Myers Co | Composition for treatment of gastro-intestinal disorders |
| US3980770A (en) * | 1971-06-04 | 1976-09-14 | Pharmacia Aktiebolag | Polymerization products containing amino groups useful in serum cholesterol level control |
| US4205064A (en) * | 1973-06-11 | 1980-05-27 | Merck & Co., Inc. | Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides] |
| US4181718A (en) * | 1975-12-29 | 1980-01-01 | Mason Norbert S | Polyanion-stabilized aluminum hydrogels |
| US4071478A (en) * | 1976-06-07 | 1978-01-31 | Merck & Co., Inc. | Controlled partially cross-linked 3,3-ionenes |
| US4183918A (en) * | 1977-03-08 | 1980-01-15 | Exxon Research & Engineering Co. | Detoxifying-medicinal emulsions |
| US4143130A (en) * | 1977-08-29 | 1979-03-06 | Warren-Teed Laboratories, Inc. | Method for treating kidney stones |
| US4247393A (en) * | 1979-01-11 | 1981-01-27 | Wallace Richard A | Hemodialysis assist device |
| US4344993A (en) * | 1980-09-02 | 1982-08-17 | The Dow Chemical Company | Perfluorocarbon-polymeric coatings having low critical surface tensions |
| US4504640A (en) * | 1982-05-19 | 1985-03-12 | Nitto Boseki Co., Ltd. | Process for producing monoallylamine polymer |
| DE3241113A1 (de) * | 1982-11-06 | 1984-05-10 | Bayer Ag, 5090 Leverkusen | Vakzinen mit zuschlagstoffen |
| JPS6090243A (ja) * | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
| CA1220897A (en) * | 1984-01-11 | 1987-04-21 | Kiyoshi Shimizu | Process for producing polymers of monoallylamine |
| US4631305A (en) * | 1985-03-22 | 1986-12-23 | The Upjohn Company | Polymeric material as a disintegrant in a compressed tablet |
| DE3541511A1 (de) * | 1985-11-19 | 1987-05-21 | Grace W R Ab | Promoter fuer die papierleimung, verfahren zu dessen herstellung und dessen verwendung |
| US6274713B1 (en) * | 1989-04-07 | 2001-08-14 | Salutar, Inc. | Polychelants |
| US5236701A (en) * | 1989-07-19 | 1993-08-17 | Lowchol Scientific Inc. | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol |
| US5053423A (en) * | 1990-03-22 | 1991-10-01 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
| IE914179A1 (en) * | 1990-12-07 | 1992-06-17 | Ici Plc | Nitrogen derivatives |
| US5055197A (en) * | 1991-04-05 | 1991-10-08 | Rohm And Haas Company | Process for removing residual monomers and oligemers from amine-containing polymers |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
| EP0580079B1 (de) * | 1992-07-22 | 1996-12-11 | Hoechst Aktiengesellschaft | Vernetzte, stickstoffhaltige Vinylcopolymere, Verfahren zu ihrer Herstellung sowie die Verwendung dieser Verbindungen |
| ES2110543T3 (es) * | 1992-07-22 | 1998-02-16 | Hoechst Ag | Derivados de poli(vinil-aminas) que tienen centros hidrofilos, procedimiento para su preparacion asi como la utilizacion de los compuestos como medicamentos, vehiculos de sustancias activas e ingredientes auxiliares para alimentos. |
| US5302531A (en) * | 1992-10-22 | 1994-04-12 | Miles Inc. | Composition for the semiquantitative determination of specific gravity of a test sample |
| US5487888A (en) * | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
| US5929184A (en) * | 1993-06-02 | 1999-07-27 | Geltex Pharmaceuticals, Inc. | Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants |
| US5667775A (en) * | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5414068A (en) * | 1994-01-24 | 1995-05-09 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
| EP0922461A4 (en) * | 1996-07-19 | 2002-07-17 | Nikken Chemicals Co Ltd | MEDICINE AGAINST HYPERPHOSPHATANEMIA |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| US6566407B2 (en) * | 1997-11-05 | 2003-05-20 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| DE69934536T2 (de) * | 1998-04-09 | 2007-10-04 | Nippon Shokubai Co. Ltd. | Vernetzes Polymerteilchen und Verfahren zu seiner Herstellung und Verwendung |
| DE19835467A1 (de) * | 1998-08-06 | 2000-02-17 | Elenac Gmbh | Feststoffreaktor mit antistatischer Beschichtung zur Durchführung von Reaktionen in der Gasphase |
| FR2799125B1 (fr) * | 1999-10-05 | 2002-01-18 | Centre Nat Rech Scient | Procede de preparation d'une composition par extraction de nacre, comprenant l'integralite des composants de la nacre, composition obtenue par ce procede et son utilisation en pharmacie et cosmetique. |
| US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| US6733780B1 (en) * | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| WO2001082871A2 (en) * | 2000-05-04 | 2001-11-08 | Ambryx Biotechnology, Inc. | Method of using zinc isotope for therapy and diagnosis of colon cancer |
| CA2444046C (en) * | 2001-04-18 | 2011-06-07 | Steven K. Burke | Use of colesevelam in reducing serum glucose |
| WO2002085380A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for treating gout and reducing serum uric acid |
| WO2002085379A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for improving vascular access in patients with vascular shunts |
| WO2002085383A1 (en) * | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Method for reducing copper levels and treating copper toxicosis |
| BR0209133A (pt) * | 2001-04-18 | 2004-06-15 | Genzyme Corp | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue |
| WO2003053932A1 (en) * | 2001-12-21 | 2003-07-03 | Tohru Koike | Zinc complexes capable of scavenging substances bearing anionic substituents |
| US20040115265A1 (en) * | 2002-12-11 | 2004-06-17 | Loutfy Benkerrour | Multilayered tablet containing pravastatin and aspirin and method |
| GB2396809A (en) * | 2003-01-03 | 2004-07-07 | Vitabiotics Ltd | Composition for the treatment of HIV and AIDS |
| WO2005065291A2 (en) * | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
| US7019085B2 (en) * | 2004-08-30 | 2006-03-28 | Albright Robert L | Phosphate selective resin and related methods |
| US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| US7985418B2 (en) * | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
-
2005
- 2005-12-29 WO PCT/US2005/047582 patent/WO2006072054A1/en not_active Ceased
- 2005-12-29 EP EP05856055A patent/EP1830832A1/en not_active Withdrawn
- 2005-12-29 JP JP2007549683A patent/JP2008526771A/ja not_active Withdrawn
-
2007
- 2007-06-19 US US11/820,297 patent/US20080014288A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526771A5 (https=) | ||
| KR102561737B1 (ko) | Ｎｏ 함유 조성물 | |
| JP2015044834A5 (https=) | ||
| JP2022124458A5 (https=) | ||
| EP2399610A3 (en) | Polymer nanoparticles coated by magnetic metal oxide and uses thereof | |
| JP2016510019A5 (https=) | ||
| JP2009502355A5 (https=) | ||
| BR112017016093B1 (pt) | composição sólida, curativo de ferida, e, método de fabricação de uma composição | |
| JP2020097577A5 (https=) | ||
| WO2010083414A8 (en) | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | |
| WO2007120853A8 (en) | Composition for controlling exposure to oxygen | |
| JP2006519852A5 (https=) | ||
| JP2011137020A5 (https=) | ||
| JP2014218522A5 (https=) | ||
| JP2016515523A5 (https=) | ||
| WO2012090225A3 (en) | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent | |
| JP2016518458A5 (https=) | ||
| WO2008005217A3 (en) | Iron(ii)-containing treatments for hyperphosphatemia | |
| EP2429517A1 (en) | Compositions suitable for the topical treatment of fungal infections of the skin and nails | |
| JP2008534453A5 (https=) | ||
| CA2530308A1 (en) | 5ht2c receptor agonists for the treatment of diabetes and obesity | |
| JP2015505295A5 (https=) | ||
| RU2012113139A (ru) | Чрескожно всасывающийся препарат | |
| JP2006509848A5 (https=) | ||
| JP2009532434A5 (https=) |